FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Mark Kaminski

Research Profile

Procedures

Chemicals & Drugs

Disorders

Concepts & Ideas

Co-author Network

Publications

TOP 3
Oliver W Press; Lisa M Rimsza; Catherine Spier; Joseph M Unger; Rita M Braziel; Bruce D Cheson; Myron S Czuczman; Shaker R Dakhil; Jonathan W Friedberg; Ajay K Gopal; Mark S Kaminski; Michael LeBlanc; David G Maloney; Thomas P Miller; Richard I Fisher
Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016.
Matthew Schipper; Anca M Avram; Mark S Kaminski; Kenneth F Koral; Yuni K Dewaraja
Prediction of therapy tumor-absorbed dose estimates in I-131 radioimmunotherapy using tracer data via a mixed-model fit to time activity.
Andrzej J Jakubowiak; Terri Jobkar; Mark S Kaminski; Daniel Lebovic; Kathryn McDonnell; Melissa Mietzel; Brian Nordgren; Keith Stockerl-Goldstein; David H Vesole; Asra Ahmed; Ammar Al-Zoubi; Tara Anderson; Daniel Couriel; Kristen Detweiler-Short; Diane E Durecki; Dominik Dytfeld; Kent Andrew Griffith; Sundar Jagannath; Ravi Vij
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Mark Kaminski (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Oliver W Press; Lisa M Rimsza; Catherine Spier; Joseph M Unger; Rita M Braziel; Bruce D Cheson; Myron S Czuczman; Shaker R Dakhil; Jonathan W Friedberg; Ajay K Gopal; Mark S Kaminski; Michael LeBlanc; David G Maloney; Thomas P Miller; Richard I Fisher
Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):314-20.
2012: Matthew Schipper; Anca M Avram; Mark S Kaminski; Kenneth F Koral; Yuni K Dewaraja
Prediction of therapy tumor-absorbed dose estimates in I-131 radioimmunotherapy using tracer data via a mixed-model fit to time activity.
Cancer biotherapy & radiopharmaceuticals 2012;27(7):403-11.
2012: Andrzej J Jakubowiak; Terri Jobkar; Mark S Kaminski; Daniel Lebovic; Kathryn McDonnell; Melissa Mietzel; Brian Nordgren; Keith Stockerl-Goldstein; David H Vesole; Asra Ahmed; Ammar Al-Zoubi; Tara Anderson; Daniel Couriel; Kristen Detweiler-Short; Diane E Durecki; Dominik Dytfeld; Kent Andrew Griffith; Sundar Jagannath; Ravi Vij
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.
Blood 2012;120(9):1801-9.
2011: Peter Ouillette; Edward M Peres; Sajid Shakhan; Kerby Shedden; Moshe Talpaz; Roxane Collins; Mark S Kaminski; Lisa Ann Kujawski; Cheng Li; Jinghui Li; Sami Malek
Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia.
Blood 2011;118(11):3051-61.
2011: Andrzej J Jakubowiak; Mark S Kaminski; Susan L Kelley; Jacob P Laubach; Sagar Lonial; Melissa A Mietzel; Noopur S Raje; Donna E Reece; Kenneth C Anderson; Tara Anderson; Jennifer C Barrickman; Erica L Campagnaro; Dixie Esseltine; Kent Andrew Griffith; Colleen K Harvey; Craig C Hofmeister; Robert L Schlossman; Craig L Tendler; Sandra M Wear; Todd M Zimmerman; Paul G Richardson
Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial.
Blood 2011;118(3):535-43.
2011: Dominik Dytfeld; Judah Friedman; Kent Andrew Griffith; Colleen Harvey; Mark S Kaminski; Daniel Lebovic; Andrzej J Jakubowiak
Superior overall survival of patients with myeloma achieving very good partial response or better to initial treatment with bortezomib, pegylated liposomal doxorubicin, and dexamethasone, predicted after two cycles by a free light chain- and M-protein-based model: extended follow-up of a phase II trial.
Leukemia & lymphoma 2011;52(7):1271-80.
2011: Kamlai Saiya-Cork; Roxane Collins; Brian Parkin; Peter Ouillette; Erlene Kuizon; Lisa Ann Kujawski; Harry P Erba; Erica Campagnaro; Kerby Shedden; Mark S Kaminski; Sami Malek
A pathobiological role of the insulin receptor in chronic lymphocytic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(9):2679-92.
2011: Peter L Roberson; Hanan Amro; Scott J Wilderman; Anca M Avram; Mark S Kaminski; Matthew Schipper; Yuni K Dewaraja
Bio-effect model applied to 131I radioimmunotherapy of refractory non-Hodgkin's lymphoma.
European journal of nuclear medicine and molecular imaging 2011;38(5):874-83.
2010: Yuni K Dewaraja; Matthew Schipper; Peter L Roberson; Scott J Wilderman; Hanan Amro; Denise D Regan; Kenneth F Koral; Mark S Kaminski; Anca M Avram
131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2010;51(7):1155-62.
2010: Brian K Link; Peter Martin; Mark S Kaminski; Stanley J Goldsmith; Morton Coleman; John P Leonard
Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(18):3035-41.
2010: Andrew D Zelenetz; Jeremy S Abramson; Ranjana H Advani; C Babis Andreadis; John C Byrd; Myron S Czuczman; Luis Fayad; Andres Forero; Martha J Glenn; Jon P Gockerman; Leo I Gordon; Nancy Lee Harris; Richard T Hoppe; Steven Horwitz; Mark S Kaminski; Youn H Kim; Ann S LaCasce; Tariq I Mughal; Auyporn Nademanee; Pierluigi Porcu; Oliver Press; Leonard Prosnitz; Nashitha Reddy; Mitchell R Smith; Lubomir Sokol; Lode Swinnen; Julie M Vose; William G Wierda; Joachim Yahalom; Furhan Yunus
NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.
Journal of the National Comprehensive Cancer Network : JNCCN 2010;8(3):288-334.
2009: Andrzej J Jakubowiak; Tara Kendall; Ammar Al-Zoubi; Yasser A Khaled; Shin Mineishi; Asra Z Ahmed; Erica Campagnaro; Christine Brozo; Thomas Braun; Moshe Talpaz; Mark S Kaminski
Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(30):5015-22.
2009: Yuni K Dewaraja; Scott J Wilderman; Kenneth F Koral; Mark S Kaminski; Anca M Avram
Use of integrated SPECT/CT imaging for tumor dosimetry in I-131 radioimmunotherapy: a pilot patient study.
Cancer biotherapy & radiopharmaceuticals 2009;24(4):417-26.
2009: Jason S Knight; Alexander Tsodikov; Diane M Cibrik; Charles W Ross; Mark S Kaminski; Douglas W Blayney
Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(20):3354-62.
2008: Lisa Ann Kujawski; Peter Ouillette; Harry P Erba; Chris Saddler; Andrzej J Jakubowiak; Mark S Kaminski; Kerby Shedden; Sami Malek
Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia.
Blood 2008;112(5):1993-2003.
2008: Richard T Hoppe; Ranjana Hira Advani; Richard F Ambinder; Philip J Bierman; Clara D Bloomfield; Kristie Blum; Bouthaina Dabaja; Benjamin Djulbegovic; Andres Forero; Leo I Gordon; Francisco J Hernandez-Ilizaliturri; Melissa M Hudson; Mark S Kaminski; Gena Love; David G Maloney; David Mansur; Peter M Mauch; Joseph O Moore; Russell J Schilder; Lawrence M Weiss; Jane N Winter; Joachim Yahalom; Andrew D Zelenetz
Hodgkin disease/lymphoma.
Journal of the National Comprehensive Cancer Network : JNCCN 2008;6(6):594-622.
2008: Andrew D Zelenetz; Ranjana H Advani; John C Byrd; Myron S Czuczman; Lloyd E Damon; Madeleine Duvic; Luis Fayad; Andres Forero; Martha J Glenn; Jon P Gockerman; Leo I Gordon; Nancy Lee Harris; Richard T Hoppe; Steven Horwitz; Mark S Kaminski; Youn H Kim; Ann S LaCasce; Auyporn Nademanee; Elise A Olsen; Pierluigi Porcu; Oliver Press; Leonard R Prosnitz; Mitchell R Smith; Eduardo M Sotomayor; Julie M Vose; Joachim Yahalom; Furhan Yunus
Non-Hodgkin's lymphomas.
Journal of the National Comprehensive Cancer Network : JNCCN 2008;6(4):356-421.
2008: Peter Ouillette; Harry P Erba; Lisa Ann Kujawski; Mark S Kaminski; Kerby Shedden; Sami Malek
Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14.
Cancer research 2008;68(4):1012-21.
2008: Chris Saddler; Peter Ouillette; Lisa Ann Kujawski; Sanjeev Shangary; Moshe Talpaz; Mark S Kaminski; Harry P Erba; Kerby Shedden; Shaomeng Wang; Sami Malek
Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia.
Blood 2008;111(3):1584-93.
2007: Mark S Kaminski
Bexxar, iodine I 131 tositumomab, effective in long-term follow-up of non-Hodgkin's lymphoma.
Cancer biology & therapy 2007;6(7):996-7.
2006: Andrew D Zelenetz; Ranjana Advani; Francis Buadi; Fernando Cabanillas; Michael A Caligiuri; Myron S Czuczman; Lloyd E Damon; Luis Fayad; Ian W Flinn; Andres Forero; Martha J Glenn; Jon P Gockerman; Leo I Gordon; Nancy Lee Harris; Richard T Hoppe; Mark S Kaminski; Ann S LaCasce; Auyporn Nademanee; Pierluigi Porcu; Oliver W Press; Leonard R Prosnitz; Mitchell R Smith; Eduardo M Sotomayor; Julie M Vose; Joachim Yahalom
Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology.
Journal of the National Comprehensive Cancer Network : JNCCN 2006;4(3):258-310.
2006: Richard T Hoppe; Ranjana Advani; Philip J Bierman; Clara D Bloomfield; Francis Buadi; Benjamin Djulgegovic; Andres Forero; Leo I Gordon; Francisco J Hernandez-Ilizaliturri; Mark S Kaminski; Gena Love; David G Maloney; Peter M Mauch; Joseph O Moore; Russell J Schilder; Lawrence Weiss; Jane N Winter; Joachim Yahalom; Andrew D Zelenetz
Hodgkin disease/lymphoma. Clinical practice guidelines in oncology.
Journal of the National Comprehensive Cancer Network : JNCCN 2006;4(3):210-30.
2005: Mark S Kaminski; John A Radford; Stephanie A Gregory; John P Leonard; Susan J Knox; Stewart Kroll; Richard L Wahl
Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(31):7985-93.
2005: Richard I Fisher; Mark S Kaminski; Richard L Wahl; Susan J Knox; Andrew D Zelenetz; Julie M Vose; John P Leonard; Stewart Kroll; Stanley J Goldsmith; Morton Coleman
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(30):7565-73.
2005: John M Bennett; Mark S Kaminski; John P Leonard; Julie M Vose; Andrew D Zelenetz; Susan J Knox; Sandra Horning; Oliver W Press; John A Radford; Stewart M Kroll; Robert L Capizzi
Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab.
Blood 2005;105(12):4576-82.
2005: Mark S Kaminski; Melissa Tuck; Judith M Estes; Arne Kolstad; Charles W Ross; Kenneth R Zasadny; Denise Regan; Paul Kison; Susan Fisher; Stewart Kroll; Richard L Wahl
131I-tositumomab therapy as initial treatment for follicular lymphoma.
The New England journal of medicine 2005;352(5):441-9.
2004: Thomas A Davis; Mark S Kaminski; John P Leonard; Frank J Hsu; Mary Wilkinson; Andrew D Zelenetz; Richard L Wahl; Stewart Kroll; Morton Coleman; Michael L Goris; Ronald Levy; Susan J Knox
The radioisotope contributes significantly to the activity of radioimmunotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(23):7792-8.
2004: Mark S Kaminski; James O Armitage
Radioimmunotherapy in the treatment of non-Hodgkin's lymphoma.
Journal of the National Comprehensive Cancer Network : JNCCN 2004;2 Suppl 3():S-54-8.
2003: Mark S Kaminski
Radioantibodies: where do they fit in?
Clinical lymphoma 2003;4(3):137-8.
2003: Kenneth F Koral; Mark S Kaminski; Richard L Wahl
Correlation of tumor radiation-absorbed dose with response is easier to find in previously untreated patients.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2003;44(9):1541-3; author reply 1543.
2003: Kenneth F Koral; Yuni K Dewaraja; Jia Li; Qiang Lin; Denise Regan; Kenneth R Zasadny; Stephen G Rommelfanger; Isaac R Francis; Mark S Kaminski; Richard L Wahl
Update on hybrid conjugate-view SPECT tumor dosimetry and response in 131I-tositumomab therapy of previously untreated lymphoma patients.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2003;44(3):457-64.
2002: Jeffrey H Muler; Riccardo Valdez; Curtis Hayes; Mark S Kaminski
Acute megakaryocytic leukemia presenting as hypercalcemia with skeletal lytic lesions.
European journal of haematology 2002;68(6):392-6.
2002: J Cooney; P Stiff; Mark S Kaminski
Successful autologous peripheral blood stem cell transplantation in transformed follicular lymphoma previously treated with radioimmunotherapy (iodine (131)I tositumomab).
Bone marrow transplantation 2002;29(6):523-5.
2002: Jeffry A Siegel; Stewart Kroll; Denise Regan; Mark S Kaminski; Richard L Wahl
A practical methodology for patient release after tositumomab and (131)I-tositumomab therapy.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2002;43(3):354-63.
2002: Kenneth F Koral; Isaac R Francis; Stewart Kroll; Kenneth R Zasadny; Mark S Kaminski; Richard L Wahl
Volume reduction versus radiation dose for tumors in previously untreated lymphoma patients who received iodine-131 tositumomab therapy. Conjugate views compared with a hybrid method.
Cancer 2002;94(4 Suppl):1258-63.
2001: Frank J Rutar; Samuel C Augustine; Mark S Kaminski; Richard L Wahl; Jeffry A Siegel; David Colcher
Feasibility and safety of outpatient Bexxar therapy (tositumomab and iodine I 131 tositumomab) for non-Hodgkin's lymphoma based on radiation doses to family members.
Clinical lymphoma 2001;2(3):164-72.
2001: Mark S Kaminski; Andrew D Zelenetz; Oliver W Press; M Saleh; J Leonard; L Fehrenbacher; T Andrew Lister; RJ Stagg; George Tidmarsh; Stewart Kroll; Richard L Wahl; Susan J Knox; Julie M Vose
Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(19):3918-28.
2001: Tone Nordøy; Arne Kolstad; Melissa Tuck; Ingeborg S Aaberge; Anne Husebekk; Mark S Kaminski
Radioimmunotherapy with iodine-131 tositumomab in patients with low-grade non-Hodgkin's B-cell lymphoma does not induce loss of acquired humoral immunity against common antigens.
Clinical immunology (Orlando, Fla.) 2001;100(1):40-8.
2000: Kenneth F Koral; Yuni K Dewaraja; J Li; C L Barrett; Denise Regan; Kenneth R Zasadny; Stephen G Rommelfanger; Isaac R Francis; Mark S Kaminski; Richard L Wahl
Initial results for Hybrid SPECT--conjugate-view tumor dosimetry in 131I-anti-B1 antibody therapy of previously untreated patients with lymphoma.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2000;41(9):1579-86.
2000: Mark S Kaminski; Judith M Estes; Kenneth R Zasadny; Isaac R Francis; Charles W Ross; Melissa Tuck; Denise Regan; Susan Fisher; J Gutierrez; Stewart Kroll; RJ Stagg; George Tidmarsh; Richard L Wahl
Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience.
Blood 2000;96(4):1259-66.
2000: Kenneth F Koral; Yuni K Dewaraja; L A Clarke; J Li; Kenneth R Zasadny; Stephen G Rommelfanger; Isaac R Francis; Mark S Kaminski; Richard L Wahl
Tumor-absorbed-dose estimates versus response in tositumomab therapy of previously untreated patients with follicular non-Hodgkin's lymphoma: preliminary report.
Cancer biotherapy & radiopharmaceuticals 2000;15(4):347-55.
2000: T Torizuka; Kenneth R Zasadny; Paul Kison; Stephen G Rommelfanger; Mark S Kaminski; Richard L Wahl
Metabolic response of non-Hodgkin's lymphoma to 131I-anti-B1 radioimmunotherapy: evaluation with FDG PET.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2000;41(6):999-1005.
2000: Julie M Vose; Richard L Wahl; M Saleh; Ama Z S Rohatiner; Susan J Knox; John A Radford; Andrew D Zelenetz; George Tidmarsh; RJ Stagg; Mark S Kaminski
Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(6):1316-23.
1999: Kenneth F Koral; J Li; Yuni K Dewaraja; C L Barrett; Denise Regan; Kenneth R Zasadny; Stephen G Rommelfanger; Isaac R Francis; Mark S Kaminski; Richard L Wahl
I-131 anti-B1 therapy/tracer uptake ratio using a new procedure for fusion of tracer images to computed tomography images.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10 Suppl):3004s-3009s.
1998: Richard L Wahl; Kenneth R Zasadny; D MacFarlane; Isaac R Francis; Charles W Ross; Judith M Estes; Susan Fisher; Denise Regan; Stewart Kroll; Mark S Kaminski
Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1998;39(8 Suppl):21S-27S.
1998: V L Gates; JE Carey; Jeffry A Siegel; Mark S Kaminski; Richard L Wahl
Nonmyeloablative iodine-131 anti-B1 radioimmunotherapy as outpatient therapy.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1998;39(7):1230-6.
1997: Kenneth F Koral; S Lin; Jeffrey A Fessler; Mark S Kaminski; Richard L Wahl
Preliminary results from intensity-based CT-SPECT fusion in I-131 anti-B1 monoclonal-antibody therapy of lymphoma.
Cancer 1997;80(12 Suppl):2538-44.
1997: Raya S Brown; Mark S Kaminski; SJ Fisher; Alfred E Chang; Richard L Wahl
Intratumoral microdistribution of [131I]MB-1 in patients with B-cell lymphoma following radioimmunotherapy.
Nuclear medicine and biology 1997;24(7):657-63.
1997: Thomas M Shehab; Mark S Kaminski; Anna S F Lok
Acute liver failure due to hepatic involvement by hematologic malignancy.
Digestive diseases and sciences 1997;42(7):1400-5.
1996: Mark S Kaminski; Kenneth R Zasadny; Isaac R Francis; M C Fenner; Charles W Ross; A W Milik; J Estes; M Tuck; D Regan; S Fisher; S D Glenn; Richard L Wahl
Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(7):1974-81.
1995: Karen F Kozarsky; L L Li; J Schaller; Mark S Kaminski; J L Claflin; David A Fox
A method for monoclonal antibody isotype switching: anti-CD60 VH expression in a heavy chain-deficient hybridoma variant.
Hybridoma 1995;14(6):597-601.
1994: Kenneth F Koral; Kenneth R Zasadny; Marc Kessler; J Q Luo; S F Buchbinder; Mark S Kaminski; Isaac R Francis; Richard L Wahl
CT-SPECT fusion plus conjugate views for determining dosimetry in iodine-131-monoclonal antibody therapy of lymphoma patients.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1994;35(10):1714-20.
1994: JS Newman; Isaac R Francis; Mark S Kaminski; Richard L Wahl
Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT.
Radiology 1994;190(1):111-6.
1993: Mark S Kaminski; Kenneth R Zasadny; Isaac R Francis; A W Milik; Charles W Ross; S D Moon; S M Crawford; J M Burgess; Neil Petry; G M Butchko
Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody.
The New England journal of medicine 1993;329(7):459-65.
1992: Donald J Buchsbaum; Richard L Wahl; Daniel Normolle; Mark S Kaminski
Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts.
Cancer research 1992;52(23):6476-81.
1992: Mark S Kaminski; Lorraine M Fig; Kenneth R Zasadny; Kenneth F Koral; R B DelRosario; Isaac R Francis; C A Hanson; Daniel Normolle; E Mudgett; C P Liu
Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(11):1696-711.
1992: Donald J Buchsbaum; Richard L Wahl; S D Glenn; Daniel Normolle; Mark S Kaminski
Improved delivery of radiolabeled anti-B1 monoclonal antibody to Raji lymphoma xenografts by predosing with unlabeled anti-B1 monoclonal antibody.
Cancer research 1992;52(3):637-42.
1991: Khalil N Bitar; Mark S Kaminski; N Hailat; Kemp B Cease; J R Strahler
Hsp27 is a mediator of sustained smooth muscle contraction in response to bombesin.
Biochemical and biophysical research communications 1991;181(3):1192-200.
1991: Richard L Wahl; Kenneth R Zasadny; Mark S Kaminski
Importance of the terminal portion of tumor time-activity curve in determining tumor dosimetry in radioimmunotherapy.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1991;32(6):1314-5.
1991: Kenneth F Koral; Kenneth R Zasadny; F M Swailem; S F Buchbinder; Isaac R Francis; Mark S Kaminski; Richard L Wahl
Importance of intra-therapy single-photon emission tomographic imaging in calculating tumour dosimetry for a lymphoma patient.
European journal of nuclear medicine 1991;18(6):432-5.
1990: Richard L Wahl; Mark S Kaminski; Stephen Ethier; G D Hutchins
The potential of 2-deoxy-2[18F]fluoro-D-glucose (FDG) for the detection of tumor involvement in lymph nodes.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1990;31(11):1831-5.
1990: M S Roth; George J Weiner; E A Allen; Valeri Terry; Catherine E Keegan; Michael Boehnke; Mark S Kaminski; David Ginsburg
Molecular characterization of anti-idiotype antibody-resistant variants of a murine B cell lymphoma.
Journal of immunology (Baltimore, Md. : 1950) 1990;145(2):768-77.
1990: George J Weiner; Mark S Kaminski
Anti-idiotypic antibodies recognizing stable epitopes limit the emergence of idiotype variants in a murine B cell lymphoma.
Journal of immunology (Baltimore, Md. : 1950) 1990;144(6):2436-45.
1989: P R Ervin; Mark S Kaminski; R L Cody; Max S Wicha
Production of mammastatin, a tissue-specific growth inhibitor, by normal human mammary cells.
Science (New York, N.Y.) 1989;244(4912):1585-7.
1989: Richard L Wahl; J R Wissing; Mark S Kaminski
Isotype switch variant anti-idiotype monoclonal antibodies: comparative radiolabeling and in vitro binding.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1989;30(2):227-32.
1989: George J Weiner; Mark S Kaminski
Idiotype variants emerging after anti-idiotype monoclonal antibody therapy of a murine B cell lymphoma.
Journal of immunology (Baltimore, Md. : 1950) 1989;142(1):343-51.
1987: Mark S Kaminski; K Kitamura; D G Maloney; Ronald Levy
Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein.
Journal of immunology (Baltimore, Md. : 1950) 1987;138(4):1289-96.
1986: T Y Basham; Mark S Kaminski; K Kitamura; Ronald Levy; T C Merigan
Synergistic antitumor effect of interferon and anti-idiotype monoclonal antibody in murine lymphoma.
Journal of immunology (Baltimore, Md. : 1950) 1986;137(9):3019-24.
1986: Mark S Kaminski; C Norman Coleman; T V Colby; R S Cox; S A Rosenberg
Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy.
Annals of internal medicine 1986;104(6):747-56.
1986: Mark S Kaminski; K Kitamura; D G Maloney; M J Campbell; Ronald Levy
Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants.
Journal of immunology (Baltimore, Md. : 1950) 1986;136(3):1123-30.
1986: M K Haseman; D A Goodwin; Claude F Meares; Mark S Kaminski; T G Wensel; M J McCall; Ronald Levy
Metabolizable 111In chelate conjugated anti-idiotype monoclonal antibody for radioimmunodetection of lymphoma in mice.
European journal of nuclear medicine 1986;12(9):455-60.
1985: D G Maloney; Mark S Kaminski; D Burowski; Joseph Haimovich; Ronald Levy
Monoclonal anti-idiotype antibodies against the murine B cell lymphoma 38C13: characterization and use as probes for the biology of the tumor in vivo and in vitro.
Hybridoma 1985;4(3):191-209.